At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
BIA 2-093 +2 moredrug
Likely dose
BIA 2-093 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 2-093, Placebo, and 1 other intervention for Epilepsy. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effects of multiple-dose administration of BIA 2-093 on the steady-state pharmacokinetics of digoxin in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPortugal
Collaborators--
Timeline
Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2002
Primary CompletionJul 2002
Study CompletionJul 2002
First PostedJun 2014
TodayJul 2026
First PostedJun 24, 2014
Enrollment StartMay 1, 2002
Primary CompletionJul 1, 2002
Study CompletionJul 25, 2002
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.0 years ago
Interventions
BIA 2-093drug
BIA 2-093 1200 mg once-daily
Placebodrug
matching placebo
Digoxindrug
Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).